DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Abilify (Aripiprazole) - Published Studies

 
 



Abilify Related Published Studies

Well-designed clinical trials related to Abilify (Aripiprazole)

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. [2014]

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. [2014]

Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. [2013]

A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. [2013]

Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes. [2013]

The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. [2013]

Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. [2013]

Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. [2013]

Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. [2011.12.02]

Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. [2011.11]

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. [2011.10]

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. [2011.09.20]

Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. [2011.09]

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). [2011.09]

The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. [2011.09]

Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. [2011.06]

Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. [2011.06]

Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. [2011.05]

An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. [2011.05]

Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. [2011.04]

Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. [2011.04]

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. [2011.04]

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. [2011.03]

Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. [2011.02.01]

Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. [2011.02]

An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. [2011.01.15]

Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. [2011]

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. [2011]

Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. [2011]

Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. [2011]

Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. [2011]

Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. [2010.12]

The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model. [2010.11]

A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). [2010.11]

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. [2010.10]

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. [2010.09]

Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. [2010.09]

Long-term treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers. [2010.08]

The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. [2010.08]

Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. [2010.07]

[A control study of aripiprazole and tiapride treatment for tic disorders in children] [2010.06]

A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. [2010.06]

Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. [2010.05.04]

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. [2010.03]

Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. [2010.02]

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. [2010.01]

Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. [2010]

Aripiprazole for the maintenance treatment of bipolar I disorder: A review. [2010]

Long-term treatment with aripiprazole on the waking and postprandial urges to smoke in Chinese heavy smokers. [2010]

Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. [2010]

A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. [2010]

The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. [2010]

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. [2009.12]

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. [2009.11]

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. [2009.10]

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. [2009.10]

Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. [2009.10]

Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. [2009.09]

Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry. [2009.08]

Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. [2009.08]

A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. [2009.08]

A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. [2009.07]

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). [2009.06]

Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. [2009.05.15]

Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. [2009.05]

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. [2009.05]

Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers. [2009.04.01]

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. [2009.04]

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. [2009.04]

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. [2009.04]

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. [2009.03.15]

Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. [2009.03]

Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. [2009.02]

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. [2009.02]

Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. [2009.02]

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. [2009.01]

A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. [2009.01]

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. [2009.01]

An Open-Label Assessment of Aripiprazole in the Treatment of PTSD. [2009]

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). [2009]

Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. [2009]

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). [2008.12.22]

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. [2008.12]

Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. [2008.12]

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.12]

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. [2008.12]

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. [2008.12]

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. [2008.11]

Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. [2008.11]

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. [2008.10]

Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. [2008.08]

A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. [2008.07]

Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. [2008.05]

Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. [2008.05]

Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. [2008.05]

Effects of aripiprazole on subjective and physiological responses to alcohol. [2008.04]

Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. [2008.04]

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.03.26]

Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.18]

Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. [2007.12]

Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. [2007.10]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017